Physicochemical characterization of a prodrug of a radionuclide decorporation agent for oral delivery

Journal of Pharmaceutical Sciences

Volumn 101, Issue 8, 2012, Pages 2844-2853

  Sueda, Katsuhiko ^a   Sadgrove, Matthew P ^a   Fitzsimmons, Jonathan M ^a   Jay, Michael ^a  

^a University of North Carolina   (United States)

Author keywords

Absorption potential; Decorporation; DTPA; Oral drug delivery; Physicochemical properties; Preformulation; Prodrugs

Indexed keywords

AMERICIUM 241; PENTETATE CALCIUM; PENTETIC ACID; PENTETIC ACID PENTAETHYL ESTER; PRODRUG; RADIOISOTOPE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; ENZYME KINETICS; FEMALE; FLOW KINETICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROLYSIS; LIPOPHILICITY; MASS SPECTROMETRY; MOLECULE; NONHUMAN; PHYSICAL CHEMISTRY; PREFORMULATION; PROTON NUCLEAR MAGNETIC RESONANCE; RADIOACTIVE CONTAMINATION; RAT; SHEAR RATE; SINGLE DRUG DOSE; SOLUBILITY; TISSUE DISTRIBUTION; VISCOSITY;

EID: 84862886370     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23218     Document Type: Article

References (42)

1. Package insert. Pentetate calcium trisodium, NDA 021749. Aug. 11, 2004.
2. Package insert. Pentetate zinc trisodium, NDA 021751. Aug. 11, 2004.
3. Agency for Toxic Substances and Disease Registry. 2004. Toxicological profile for americium. AtlantaGeorgia: U.S. Department of Health and Human Services, Public Health Service.
4. Agency for Toxic Substances and Disease Registry. 2010. Toxicological profile for plutonium. AtlantaGeorgia: U.S. Department of Health and Human Services, Public Health Service.
5. 14C-DTPA in human volunteers after inhalation or intravenous injection. Health Phys 44(1):45-52.
6. Crawley FEH, Haines JW. 1979. The dosimetry of carbon-14 labelled compounds: The metabolism of diethylenetriaminepentaacetic acid (DTPA) in the rat. Int J Nucl Med Biol 6:9-15.
7. Gerber GB, Thomas RG. 1992. Guidebook for the treatment of accidental internal radionuclide contamination of workers. Radiat Prot Dosimetry 41(1):27-36.
8. Fritsch P, Serandour AL, Gremy O, Phan G, Tsapis N, Fattal E, Benech H, Deverre JR, Poncy JL. 2010. Structure of a single model to describe plutonium and americium decorporation by DTPA treatments. Health Phys 99(4):553-559.
9. Lloyd RD, Jones CW, Taylor GN, Mays CW, Atherton DR. 1979. Pu and Am decorporation in beagles: Effects of magnitude of initial Ca-DTPA injection upon chelation efficacy. Radiat Res 79(3):630-634.
10. Taylor DM, Sowby FD. 1962. The removal of americium and plutonium from the rat by chelating agents. Phys Med Biol 7:83-91.
11. Stradling GN, Henge-Napoli MH, Paquet F, Poncy JL, Fritsch P, Taylor DM. 2000. Optimum treatment regimens with animals. Radiat Prot Dosimetry 87:29-40.
12. 242Cm from the rat. Radiat Res 70:164-172.
13. Breitenstein BD Jr, Palmer HE. 1989. Lifetime follow-up of the 1976 americium accident victim. Radiat Pro Dosimetry 26:317-322.
14. Lloyd RD, Taylor GN, Mays CW, Jones CW, Bruenger FW, Atherton DR. 1979. Dependency of chelation efficacy upon time after first DTPA injection. Radiat Res 78:448-454.
15. Volf V. 1984. Effect of drinking Zn-DTPA on 238-Pu and 241-Am in rat bones. Radiat Environ Biophys 23:141-143.
16. Beaumont K, Webster R, Gardner I, Dack K. 2003. Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: Challenges to the discovery scientist. Curr Drug Metab 4:461-485.
17. Ettmayer P, Amidon GL, Clement B, Testa B. 2004. Lessons learned from marketed and investigational prodrugs. J Med Chem 47:2393-2404.
18. Rautio J, Kumpulainen H, Heimbach T, Oliyai R, Oh D, Jarvinen T, Savolainen J. 2008. Prodrugs: Design and clinical applications. Nat Rev Drug Discov 7(3):255-270.
19. Guilmette RA, Parks JE, Lindenbaum A. 1979. Synthesis and therapeutic testing of mono- and dialkyl esters of pentetic (diethylenetriaminepentaacetic) acid for decorporation of polymeric plutonium. J Pharm Sci 68:194-196.
20. Markley JF. 1963. Removal of polymeric plutonium from mice by combined therapy with the calcium chelate and penta-ethyl ester of DTPA. Int J Radiat Biol 7:405-407.
21. Bruenger FW, Kuswik-Rabiega G, Miller SC. 1992. Decorporation of aged americium deposits by oral administration of lipophilic polyamino carboxylic acids. J Med Chem 35:112-118.
22. Miller SC, Wang X, Bowman BM. 2010. Pharmacological properties of orally available amphipathic polyaminocarboxylic acid chelators for actinide decorporation. Health Phys 99:408-412.
23. Lachenmeier DW, Haupt S, Schulz K. 2008. Defining maximum levels of higher alcohols in alcoholic beverages and surrogate alcohol products. Regul Toxicol Pharmacol 50:313-321.
24. Jay M, Mumper RJ. 2011. Methods and pharmaceutical compositions for decorporation of radioactive compounds. Patent US8030358.
25. United States Pharmacopeia-The National Formulary, USP 34-NF 29. 2011. Rockville, Maryland: The United States Pharmacopeial Convention.
26. Sudmeier JL, Reilley CN. 1964. Nuclear magnetic resonance studies of protonation of polyamine and aminocarboxylate compounds in aqueous solution. Anal Chem 36(9):1698-1706.
27. 3+ binding to model DTPA-conjugates and DTPA-proteins: Implications for their use as magnetic resonance contrast agents. Magn Reson Med 8:180-190.
28. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. 1997. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Delivery Rev 23:3-25.
29. Lee CP, de Vrueh RLA, Smith PL. 1997. Selection of development candidates based on in vitro permeability measurements. Adv Drug Delivery Rev 23:47-62.
30. ChemBioDraw Ultra 11.0.1. Cambridge, Massachusetts: CambridgeSoft.
31. Fleisher D, Li C, Zhou Y, Pao L-H, Karim A. 1999. Drug, meal and formulation interactions influencing drug absorption after oral administration. Clin Pharmacokinet 36:233-254.
32. Lokshina LA, Orekhovich VN, Sklyankina VA. 1964. Esterase activity of pepsin. Nature 204:580.
33. MacGregor KJ, Embleton JK, Lacy JE, Perry EA, Solomon LJ, Seager H, Pouton CW. 1997. Influence of lipolysis on drug absorption from the gastro-intestinal tract. Adv Drug Delivery Rev 25:33-46.
34. Gao P, Morozowich W. 2006. Development of supersaturable self-emulsifying drug delivery system formulations for improving the oral absorption of poorly soluble drugs. Expert Opin Drug Deliv 3(1):97-110.
35. Porter CJH, Trevaskis NL, Charman WN. 2007. Lipids and lipid-based formulations: Optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov 6:231-248.
36. Phan G, Herbet A, Cholet S, Benech H, Deverre J-R, Fattal E. 2005. Pharmacokinetics of DTPA entrapped in conventional and long-circulating liposomes of different size for plutonium decorporation. J Control Release 110:177-188.
37. Guilmette RA, Muggenburg BA. 1988. Reducing the radiation dose from inhaled americium-241 using continuously administered DTPA therapy. Int J Radiat Biol 53(2):261-271.
38. Stradling GN, Stather JW, Gray SA, Moody JC, Ellender M, Hodgson A, Volf V, Taylor DM, Wirth P, Gaskin PW. 1989. The efficacies of pure LICAM(C) and DTPA on the retention of plutonium-238 and americium-241 in rats after their inhalation as nitrates and intravenous injection as citrate. Int J Radiat Biol 56(4):503-514.
39. Guilmette RA, Durbin PW. 2003. Scientific basis for the development of biokinetic models for radionuclide-contaminated wounds. Radiat Prot Dosimetry 105(1-4):213-218.
40. Hosokawa M. 2008. Structure and catalytic properties of carboxylesterase isozymes involved in metabolic activation of prodrugs. Molecules 13:412-431.
41. Liederer BM, Borchardt RT. 2006. Enzymes involved in the bioconversion of ester-based prodrugs. J Pharm Sci 95(6):1177-1195.
42. Imai T. 2006. Human carboxylesterase isozymes: Catalytic properties and rational drug design. Drug Metab Pharmacokinet 21(3):173-185.